Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study
- 1 March 2020
- journal article
- letter
- Published by Elsevier in Joint Bone Spine
- Vol. 87 (2) , 179-180
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Expert opinion on the use of biological therapy in non-infectious uveitisExpert Opinion on Biological Therapy, 2019
- Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 PatientsAmerican Journal of Ophthalmology, 2019
- Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patientsJournal of Autoimmunity, 2018
- Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature reviewCritical Care, 2018
- Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATEJoint Bone Spine, 2018
- Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal studyAnnals of the Rheumatic Diseases, 2016
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsRheumatology, 2010
- Tocilizumab: Therapy and safety managementJoint Bone Spine, 2010